RxDoctor Payments Data

Glen Bianchi, MD

Ophthalmology · Westwood, NJNPI 1780636019

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 39.1% of the total. Reporting peaked in 2023 at $293 and has fallen 78.0% since, to $64 in 2025. That places this record below the midpoint for ophthalmology clinicians in NJ, where the typical reported total is $1,407.

$1,331in general payments, 2019–2025

Across 56 payments — averaging $23.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$521
  • Santen Inc.$110
  • Alcon$107
  • Coopervision Inc.$88
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$87
  • Novartis$65
  • plus $353 from 14 others

What the payments were for

  • Food & beverage$1,29297%
  • Education$30%
  • Gifts$373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,331 in reported general payments places this provider in the 45th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$52,645
Medicare patients
226
Services billed
460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$328
Latanoprost19$267
Ofloxacin11$90

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Westwood

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →